Bullous Pemphigoid

 The supplemental biologics license application for Dupixent for the treatment of bullous pemphigoid in adults has been accepted by the FDA for priority review, Sanofi announced in a press release.

Patients with bullous pemphigoid treated with Dupixent maintained disease control and symptom relief, according to phase 2/3 trial results released by Regeneron and Sanofi.

A low dose of interleukin-2 therapy showed positive results in the treatment of bullous pemphigoid with an early onset of response, according to a study.

Rapid itch reduction was positively correlated with treatment response among patients taking dupilumab for bullous pemphigoid, according to a study.

Clinicians should consider dupilumab as a therapeutic option for bullous pemphigoid due to its ability to clear blistering and pruritus safely, according to a study.

The Skindex-16, a clinical tool for measuring the skin-related quality of life of patients, showed that patients with autoimmune bullous diseases are greatly impacted by disease flares, according to a study.

Patients with bullous pemphigoid experienced symptom improvement with dupilumab treatment, according to a study.

Nomacopan was well tolerated and beneficial in patients with bullous pemphigoid, according to phase 2a clinical trial results.

Researchers identified three different clusters of bullous pemphigoid, the most common autoimmune blistering disorder, according to a study published in the Journal of American Academy of Dermatology.

The humoral response to BP180 and BP230 antigens is weakened in certain patients with gliptin-associated bullous pemphigoid, according to a study.